SMT201500281B - Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari - Google Patents

Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari

Info

Publication number
SMT201500281B
SMT201500281B SM201500281T SM201500281T SMT201500281B SM T201500281 B SMT201500281 B SM T201500281B SM 201500281 T SM201500281 T SM 201500281T SM 201500281 T SM201500281 T SM 201500281T SM T201500281 B SMT201500281 B SM T201500281B
Authority
SM
San Marino
Prior art keywords
rostafuroxine
cardiovascular conditions
pharmacogenomic treatment
pharmacogenomic
treatment
Prior art date
Application number
SM201500281T
Other languages
English (en)
Inventor
Giuseppe Bianchi
Patrizia Ferrari
Fabio Macciardi
Original Assignee
Rostaquo S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rostaquo S P A filed Critical Rostaquo S P A
Publication of SMT201500281B publication Critical patent/SMT201500281B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
SM201500281T 2009-10-19 2015-11-12 Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari SMT201500281B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25302009P 2009-10-19 2009-10-19
EP09177111 2009-11-25
PCT/EP2010/065589 WO2011048033A2 (en) 2009-10-19 2010-10-18 Methods and systems for pharmacogenomic treatment of cardiovascular conditions
EP10807525.0A EP2490694B1 (en) 2009-10-19 2010-10-18 Rostafuroxine for pharmacogenomic treatment of cardiovascular conditions

Publications (1)

Publication Number Publication Date
SMT201500281B true SMT201500281B (it) 2016-01-08

Family

ID=41727473

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500281T SMT201500281B (it) 2009-10-19 2015-11-12 Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari

Country Status (23)

Country Link
US (1) US9408854B2 (it)
EP (1) EP2490694B1 (it)
JP (3) JP2013508329A (it)
KR (3) KR102053470B1 (it)
CN (1) CN102695512B (it)
AU (1) AU2010309921B2 (it)
BR (1) BR112012009144B8 (it)
CA (1) CA2777310C (it)
DK (1) DK2490694T3 (it)
EA (1) EA201270574A1 (it)
ES (1) ES2551877T3 (it)
HR (1) HRP20151185T1 (it)
HU (1) HUE028075T2 (it)
IL (1) IL219173A (it)
ME (1) ME02347B (it)
MX (1) MX2012004559A (it)
PL (1) PL2490694T3 (it)
PT (1) PT2490694E (it)
RS (1) RS54416B1 (it)
SG (1) SG10201406457VA (it)
SI (1) SI2490694T1 (it)
SM (1) SMT201500281B (it)
WO (1) WO2011048033A2 (it)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640847A1 (en) * 2010-11-19 2013-09-25 Fondazione Centro San Raffaele del Monte Tabor Markers for acute kidney injury and uses thereof
CN102940640A (zh) * 2012-12-06 2013-02-27 中国生命药物治疗有限公司 罗他夫辛在制备治疗基因缺陷型原发性高血压的药物中的用途
EP2937421B1 (en) * 2014-04-03 2018-10-24 Samsung Electronics Co., Ltd Biomarker for predicting effect of an anti-C-met antibody
KR102338678B1 (ko) * 2014-04-03 2021-12-13 삼성전자주식회사 항 c-Met 항체 효과 예측을 위한 바이오마커
WO2015183938A1 (en) * 2014-05-29 2015-12-03 Geneticure Llc Improved therapeutic regimen for hypertension
US11761043B2 (en) 2014-05-29 2023-09-19 Geneticure Inc. Machine assay and analysis for selecting antihypertensive drugs
EP2977758A1 (en) * 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
CN107447014A (zh) * 2015-01-21 2017-12-08 田小利 Thsd7a基因序列及表达改变检测及其在冠心病预测中的应用
CA3018186C (en) * 2016-03-29 2023-06-13 Regeneron Pharmaceuticals, Inc. Genetic variant-phenotype analysis system and methods of use
CN108728522A (zh) * 2018-06-11 2018-11-02 苏州艾达康医疗科技有限公司 药物基因组检测方法
US11337988B2 (en) 2018-09-27 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ouabain antagonists to inhibit viral infection
US11894121B2 (en) 2021-08-06 2024-02-06 Reviv Global Ltd Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods
US11600375B2 (en) 2021-07-30 2023-03-07 Reviv Global Ltd Genetically personalized food recommendation systems and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001181D0 (en) 1990-01-18 1990-03-21 Imp Cancer Res Tech Genetic assay
DE4227616C2 (de) 1992-08-20 1995-04-13 Sigma Tau Ind Farmaceuti 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen
US5632276A (en) 1995-01-27 1997-05-27 Eidelberg; David Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same
SE9501782D0 (sv) 1995-05-12 1995-05-12 Landstinget I Oestergoetland Method of predicting the therapeutic response of a drug against a malignant tumour
US6566332B2 (en) * 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US20020132234A1 (en) * 2000-01-24 2002-09-19 Moskowitz David W. Nitric oxide synthase gene diagnostic polymorphisms
AU2001257421A1 (en) 2000-04-28 2001-11-12 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20040166491A1 (en) * 2001-08-09 2004-08-26 Henderson Lee A Vhl promoter diagnostic polymorphism
EP1427849B1 (en) 2001-08-21 2013-05-15 VIIV Healthcare UK Limited Method of screening for drug hypersensitivity reaction
US20050065079A1 (en) * 2001-10-12 2005-03-24 Aaron Scalia Ngzipa,ngzipd,pgzipa and pgzipd polynucleotides and polypeptides and uses thereof
WO2003095485A2 (en) * 2002-05-10 2003-11-20 Serono Genetics Institute S.A. Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
CA2518957A1 (en) 2003-03-10 2004-09-23 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
CA2581086C (en) 2004-09-14 2023-11-07 The Regents Of The University Of Colorado, A Body Corporate Method for treatment with bucindolol based on genetic targeting
PL1951738T3 (pl) * 2005-11-25 2012-06-29 Cvie Therapeutics Ltd Nowe formy krystaliczne rostafuroksyny
JP4974091B2 (ja) * 2007-07-06 2012-07-11 独立行政法人放射線医学総合研究所 放射線治療後における泌尿器の晩期有害反応の発症予測用ｄｎａチップ、及びこれを用いた放射線治療後における泌尿器の晩期有害反応の発症予測方法
JP5476536B2 (ja) * 2007-10-03 2014-04-23 独立行政法人放射線医学総合研究所 乳癌の放射線治療による晩期副作用の発症を予測する方法
US20090221620A1 (en) * 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
JP2010106007A (ja) 2008-08-14 2010-05-13 Sony Corp 薬剤徐放剤、吸着剤、機能性食品、マスク及び吸着シート
JP5738267B2 (ja) * 2009-03-23 2015-06-24 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ タンパク尿、糸球体硬化、及び腎不全の治療に有用な５−β，１４−β−アンドロスタン誘導体

Also Published As

Publication number Publication date
JP2013508329A (ja) 2013-03-07
BR112012009144B8 (pt) 2021-05-25
EP2490694A2 (en) 2012-08-29
CA2777310C (en) 2018-08-28
IL219173A (en) 2017-08-31
CN102695512B (zh) 2017-05-10
US9408854B2 (en) 2016-08-09
HRP20151185T1 (hr) 2015-12-04
CN102695512A (zh) 2012-09-26
KR20120093297A (ko) 2012-08-22
CA2777310A1 (en) 2011-04-28
PL2490694T3 (pl) 2016-02-29
DK2490694T3 (en) 2015-11-30
BR112012009144A2 (pt) 2018-10-16
SI2490694T1 (sl) 2015-12-31
AU2010309921B2 (en) 2017-04-13
EP2490694B1 (en) 2015-09-16
ME02347B (me) 2016-06-20
HUE028075T2 (en) 2016-11-28
MX2012004559A (es) 2012-12-05
WO2011048033A2 (en) 2011-04-28
IL219173A0 (en) 2012-06-28
JP2014040418A (ja) 2014-03-06
JP6130268B2 (ja) 2017-05-17
SG10201406457VA (en) 2014-11-27
KR102053470B1 (ko) 2019-12-06
KR20140060323A (ko) 2014-05-19
PT2490694E (pt) 2015-12-02
AU2010309921A1 (en) 2012-05-03
KR20170121325A (ko) 2017-11-01
BR112012009144B1 (pt) 2020-12-01
RS54416B1 (en) 2016-04-28
WO2011048033A3 (en) 2011-07-14
JP2015128435A (ja) 2015-07-16
EA201270574A1 (ru) 2012-12-28
US20130018024A1 (en) 2013-01-17
ES2551877T3 (es) 2015-11-24

Similar Documents

Publication Publication Date Title
SMT201500281B (it) Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari
SMT201600254B (it) Procedimento per la preparazione di idromagnesite
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
SI2403852T1 (sl) 2-aminobenzimidazol-5-karboksamidi kot protivnetna sredstva
RS59850B1 (sr) Bardoksolon metil za lečenje gojaznosti
IT1393061B1 (it) Procedimento integrato per la produzione di bio-olio da microrganismi
GB0915515D0 (en) Treatment of vasculoproliferative conditions
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
ZA201107445B (en) Compound for the treatment of metabolic disorders
SMT201400165B (it) Composizioni e metodi per il trattamento di sclerosi multipla
IT1398729B1 (it) Processo per la preparazione di testosterone
IL215377A0 (en) Method of genotyping
IT1403587B1 (it) Composizione per il trattamento di disordini metabolici
HK1175072A1 (en) 2-aminoindole compounds and methods for the treatment of malaria 2-
GB0903740D0 (en) Mrthod for reducing the viscosity of biosolids
IT1394292B1 (it) Procedimento per la sintesi di pregabalina
IT1399040B1 (it) Procedimento per il rinforzo di elementi strutturali
TWM370404U (en) Structure of compound massage set
IT1398273B1 (it) Procedimento per la preparazione di 14-bromo daunomicina
IT1397499B1 (it) Processo per la preparazione di ciclesonide
TH126327B (th) กระบวนการสำหรับการเตรียมเอไมด์
GB0804468D0 (en) Treatment of influenza
GB0904423D0 (en) Improving the solubility of chemicals